These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8278817)

  • 21. Severe rheumatoid arthritis: current options in drug therapy.
    Kremer JM
    Geriatrics; 1990 Dec; 45(12):43-8. PubMed ID: 2123816
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort.
    Rannio T; Asikainen J; Hannonen P; Yli-Kerttula T; Ekman P; Pirilä L; Kuusalo L; Mali M; Puurtinen-Vilkki M; Kortelainen S; Paltta J; Taimen K; Kauppi M; Laiho K; Nyrhinen S; Mäkinen H; Isomäki P; Uotila T; Aaltonen K; Kautiainen H; Sokka T
    Scand J Rheumatol; 2017 Nov; 46(6):425-431. PubMed ID: 28367663
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.
    Karlsson JA; Neovius M; Nilsson JÅ; Petersson IF; Bratt J; van Vollenhoven RF; Ernestam S; Geborek P
    Ann Rheum Dis; 2013 Dec; 72(12):1927-33. PubMed ID: 23196701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The place of methotrexate in the treatment of rheumatoid arthritis. Introduction.
    Hoffmeister RT
    Semin Arthritis Rheum; 1991 Oct; 21(2 Suppl 1):1-3. PubMed ID: 1749944
    [No Abstract]   [Full Text] [Related]  

  • 25. A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study.
    Heimans L; Wevers-de Boer KV; Visser K; Goekoop RJ; van Oosterhout M; Harbers JB; Bijkerk C; Speyer I; de Buck MP; de Sonnaville PB; Grillet BA; Huizinga TW; Allaart CF
    Ann Rheum Dis; 2014 Jul; 73(7):1356-61. PubMed ID: 23716067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Toxicity of anti-rheumatic drugs in a randomized clinical trial of early rheumatoid arthritis.
    van Jaarsveld CH; Jahangier ZN; Jacobs JW; Blaauw AA; van Albada-Kuipers GA; ter Borg EJ; Brus HL; Schenk Y; van Der Veen MJ; Bijlsma JW
    Rheumatology (Oxford); 2000 Dec; 39(12):1374-82. PubMed ID: 11136881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term results of the FIN-RACo trial; treatment with a combination of traditional disease-modifying anti-rheumatic drugs is an excellent option in early rheumatoid arthritis.
    Rantalaiho V; Puolakka K; Korpela M; Hannonen P; Möttönen T
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S27-31. PubMed ID: 23073350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disease-modifying anti-rheumatic drug therapy and structural damage in early rheumatoid arthritis.
    Mullan RH; Bresnihan B
    Clin Exp Rheumatol; 2003; 21(5 Suppl 31):S158-64. PubMed ID: 14969069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Utrecht experience with different treatment strategies in early rheumatoid arthritis.
    Verstappen SM; Jacobs JW; Bijlsma JW;
    Clin Exp Rheumatol; 2003; 21(5 Suppl 31):S165-8. PubMed ID: 14969070
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Etanercept-Methotrexate Combination Therapy Initiators Have Greater Adherence and Persistence Than Triple Therapy Initiators With Rheumatoid Arthritis.
    Bonafede M; Johnson BH; Tang DH; Shah N; Harrison DJ; Collier DH
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1656-63. PubMed ID: 26097194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts.
    Wolfe F; Hawley DJ; Cathey MA
    J Rheumatol; 1990 Aug; 17(8):994-1002. PubMed ID: 1976811
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Evidence-based treatment of methotrexate-resistant rheumatoid arthritis. Combinations of conventional disease-modifying antirheumatic agents].
    Schnabel A; Gross WL
    Dtsch Med Wochenschr; 2003 Jan; 128(4):147-9. PubMed ID: 12589584
    [No Abstract]   [Full Text] [Related]  

  • 33. Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis.
    Cummins L; Katikireddi VS; Shankaranarayana S; Su KY; Duggan E; Videm V; Pahau H; Thomas R
    Intern Med J; 2015 Dec; 45(12):1266-73. PubMed ID: 26384029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The influence of methotrexate on the gene expression of the pro-inflammatory cytokine IL-12A in the therapy of rheumatoid arthritis.
    Hobl EL; Mader RM; Erlacher L; Duhm B; Mustak M; Bröll H; Högger P; Kalipciyan M; Jilma B
    Clin Exp Rheumatol; 2011; 29(6):963-9. PubMed ID: 22133036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic factors in a large cohort of patients with early undifferentiated inflammatory arthritis after application of a structured management protocol.
    Quinn MA; Green MJ; Marzo-Ortega H; Proudman S; Karim Z; Wakefield RJ; Conaghan PG; Emery P
    Arthritis Rheum; 2003 Nov; 48(11):3039-45. PubMed ID: 14613264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of bucillamine, a D-penicillamine analogue, in patients with active rheumatoid arthritis.
    Sekiguchi N; Kameda H; Amano K; Takeuchi T
    Mod Rheumatol; 2006; 16(2):85-91. PubMed ID: 16633927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies.
    Saunders SA; Capell HA; Stirling A; Vallance R; Kincaid W; McMahon AD; Porter DR
    Arthritis Rheum; 2008 May; 58(5):1310-7. PubMed ID: 18438851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial.
    van Vollenhoven RF; Ernestam S; Geborek P; Petersson IF; Cöster L; Waltbrand E; Zickert A; Theander J; Thörner A; Hellström H; Teleman A; Dackhammar C; Akre F; Forslind K; Ljung L; Oding R; Chatzidionysiou A; Wörnert M; Bratt J
    Lancet; 2009 Aug; 374(9688):459-66. PubMed ID: 19665644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rational use of new and existing disease-modifying agents in rheumatoid arthritis.
    Kremer JM
    Ann Intern Med; 2001 Apr; 134(8):695-706. PubMed ID: 11304108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis.
    Sauer BC; Teng CC; Tang D; Leng J; Curtis JR; Mikuls TR; Harrison DJ; Cannon GW
    Arthritis Care Res (Hoboken); 2017 Mar; 69(3):313-322. PubMed ID: 27273801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.